PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
799.80%
Cash & equivalents growing 799.80% while TRAW's declined -12.27%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
799.80%
Below half of TRAW's -12.27%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
700.88%
Below half of TRAW's -12.19%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-9.67%
Below half TRAW's 27.66%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.93%
Below half of TRAW's 6.60%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
569.03%
Below half of TRAW's -12.08%. Michael Burry sees a potential red flag for stagnation or capital shortage.
1.26%
Less than half of TRAW's 23.07%. David Dodd sees a more disciplined AP approach or lower volume.
-42.54%
Higher Short-Term Debt Growth compared to TRAW's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
5.04%
Higher Deferred Revenue (Current) Growth compared to TRAW's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
-1.15%
Less than half of TRAW's 26.64%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-16.72%
Higher Total Non-Current Liabilities Growth compared to TRAW's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-2.99%
Less than half of TRAW's 17.17%. David Dodd sees far fewer liability expansions relative to competitor.
-92.57%
Less than half of TRAW's 4.06%. David Dodd sees fewer share issuances vs. competitor.
-2.16%
1.25-1.5x TRAW's -1.81%. Bruce Berkowitz notes stronger reinvestment strategy.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1581.26%
Below half TRAW's -26.77%. Michael Burry sees potential underperformance in building shareholder capital.
569.03%
Below half TRAW's -12.08%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-16.19%
Higher Total Debt Growth compared to TRAW's zero value, indicating worse performance.
-1028.99%
Less than half of TRAW's 12.27%. David Dodd sees better deleveraging or stronger cash buildup than competitor.